Eventually, marrow HSC loss due to in situ differentiation or migration from the marrow and sequestration in the spleen, together with continued megakaryocyte stimulation by the elevated plasma THPO, produces a PMF phenotype, regardless of the MPN driver mutation. The gene discussed is THPO; the disease is myeloproliferative disorder.